Correspondence 0000950170-23-009167 from Tracon Pharmaceuticals, Inc. (TCON) (CIK 0001394319)
Tracon Pharmaceuticals, Inc. (TCON) (CIK 0001394319)
Date: March 22, 2023 · CIK: 0001394319 · Accession: 0000950170-23-009167
AI Filing Summary & Sentiment
File numbers found in text: 333-270589
Letter
TRACON Pharmaceuticals, Inc.
4350 La Jolla Village Drive, Suite 800
San Diego, California 92122
March 22, 2023
Via EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
RE: TRACON Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-270589
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on March 24, 2023, or as soon thereafter as is practicable.
Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Matthew Browne of Cooley LLP, counsel to the Registrant, at (858) 550-6045.
TRACON Pharmaceuticals, inc.
By: /s/ Scott Brown
Scott Brown
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP TRACON Pharmaceuticals, Inc. 4350 La Jolla Village Drive, Suite 800 San Diego, California 92122 March 22, 2023 Via EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama RE: TRACON Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-270589 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on March 24, 2023, or as soon thereafter as is practicable. Once the above-referenced Registration Statement has been declared effective, please orally confirm that event with Matthew Browne of Cooley LLP, counsel to the Registrant, at (858) 550-6045. TRACON Pharmaceuticals, inc. By: /s/ Scott Brown Scott Brown Chief Financial Officer